Skip to Main Content

Author Details

Sian Fereday
Peter MacCallum Cancer Centre
2001
56
29
PMIDPaper TitleJournal TitlePublished Year
36366810Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.J Gynecol Oncol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36366810Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan.J Gynecol Oncol2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36790339Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma.Cancer Epidemiol Biomarkers Prev2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
36849657Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.Nat Genet2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
35400525Germline BRCA variants, lifestyle and ovarian cancer survival.Gynecol Oncol2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
35263119TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.J Clin Oncol2022
35400525Germline BRCA variants, lifestyle and ovarian cancer survival.Gynecol Oncol2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
35263119TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.J Clin Oncol2022
34162658Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer.Cancer Epidemiol Biomarkers Prev2021
34162658Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer.Cancer Epidemiol Biomarkers Prev2021
34031395Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.Nat Commun2021
34184547Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.Biomark Med2021
34184547Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.Biomark Med2021
34031395Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.Nat Commun2021
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
31076661Going to extremes: determinants of extraordinary response and survival in patients with cancer.Nat Rev Cancer2019
31076661Going to extremes: determinants of extraordinary response and survival in patients with cancer.Nat Rev Cancer2019
30967419Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.Clin Cancer Res2019
30894541Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.Nat Commun2019
30721246Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma.PLoS One2019
30894541Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.Nat Commun2019
30967419Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.Clin Cancer Res2019
30721246Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma.PLoS One2019
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
35135122<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.JCO Precis Oncol2018
30062862Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2018
29531130Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev2018
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
29061645Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.Clin Cancer Res2018
  • 1 - 50 of 112

Recommended Authors

Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 8
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 5
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 16
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 1
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 8
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 13
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 1
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 19
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 3
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Celeste Yu
Cancer Clinical Research Unit, Princess Margaret Cancer Centre
Career Start Year 2006
Number of shared co-authors 2
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 4
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 26
Jennifer B Permuth
Moffitt Cancer Center
Career Start Year 2004
Number of shared co-authors 90
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 0
Karin Jirstr??m
Lund University
Career Start Year 2003
Number of shared co-authors 5
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 18
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 3
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 33
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 4
Saravut J Weroha
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 21
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 1
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 19
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 7
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 4
Anil K Sood
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 40
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 11
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 78

Collaborators

David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 46
Anna DeFazio
Westmead Hospital
Co-authored papers 43
Nadia Traficante
Peter MacCallum Cancer Centre
Co-authored papers 22
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 20
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 18
Paul Harnett
Westmead Clinical School, University of Sydney
Co-authored papers 18
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 18
Michael S Anglesio
University of British Columbia
Co-authored papers 17
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 17
Martin K??bel
University of Calgary
Co-authored papers 16
Kathryn Alsop
Peter MacCallum Cancer Centre
Co-authored papers 16
Joy Hendley
Peter MacCallum Cancer Centre
Co-authored papers 15
Joshy George
Peter MacCallum Cancer Centre
Co-authored papers 15
James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 15
David G Huntsman
University of British Columbia
Co-authored papers 15
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 13
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 13
Dariush Etemadmoghadam
Peter MacCallum Cancer Centre
Co-authored papers 13
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 12
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 12
Stacey J Winham
Mayo Clinic
Co-authored papers 12
Raghwa Sharma
Westmead Hospital
Co-authored papers 11
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 11
Celeste Leigh Pearce
University of Michigan School of Public Health ann arbor
Co-authored papers 11
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 11
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 10
Malcolm C Pike
Memorial Sloan-Kettering Cancer Center
Co-authored papers 10
Jennifer Alsop
University of Cambridge
Co-authored papers 10
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 10
Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 10
Release 1.2